大型制药公司与印度专利局的较量 - Suppr

Suppr

超能文献

Big Pharma vs India’s Patent Office.

出版信息

Pharm Pat Anal. 2012 Nov;1(5):529. doi: 10.4155/ppa.12.72.

DOI:10.4155/ppa.12.72

PMID:24236921

Abstract

摘要

相似文献

Big Pharma vs India’s Patent Office.

Pharm Pat Anal. 2012 Nov;1(5):529. doi: 10.4155/ppa.12.72.

India's patent case victory rattles Big Pharma.

Lancet. 2013 Apr 13;381(9874):1263. doi: 10.1016/s0140-6736(13)60826-0.

India's rejection of Novartis's patent is but a small step in the right direction.

BMJ. 2013 Apr 17;346:f2412. doi: 10.1136/bmj.f2412.

Intellectual property. Challenges to India's pharmaceutical patent laws.

Science. 2012 Jul 27;337(6093):414-5. doi: 10.1126/science.1224892. Epub 2012 Jul 5.

Engineered in India--patent law 2.0.

N Engl J Med. 2013 Aug 8;369(6):497-9. doi: 10.1056/NEJMp1304400. Epub 2013 Jul 17.

Taking TRIPS to India--Novartis, patent law, and access to medicines.

N Engl J Med. 2007 Feb 8;356(6):541-3. doi: 10.1056/NEJMp068245.

The Indian Supreme Court's judgment in the case of Glivec(®) - the uncertain future of pharmaceutical patents in India.

Pharm Pat Anal. 2014 Mar;3(2):117-9. doi: 10.4155/ppa.14.8.

Supreme Court of India rejects Novartis’ cancer drug patent.

Pharm Pat Anal. 2013 May;2(3):299-300. doi: 10.4155/ppa.13.28.

Will the refusal of patent protection for Glivec® discourage future pharmaceutical innovation in India?

Pharm Pat Anal. 2013 Jul;2(4):439-41. doi: 10.4155/ppa.13.36.

Indian Supreme Court rejects Novartis's appeal on drug patent.

BMJ. 2013 Apr 2;346:f2099. doi: 10.1136/bmj.f2099.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Big Pharma vs India’s Patent Office.

Pharm Pat Anal. 2012 Nov;1(5):529. doi: 10.4155/ppa.12.72.

India's patent case victory rattles Big Pharma.

Lancet. 2013 Apr 13;381(9874):1263. doi: 10.1016/s0140-6736(13)60826-0.

India's rejection of Novartis's patent is but a small step in the right direction.

BMJ. 2013 Apr 17;346:f2412. doi: 10.1136/bmj.f2412.

Intellectual property. Challenges to India's pharmaceutical patent laws.

Science. 2012 Jul 27;337(6093):414-5. doi: 10.1126/science.1224892. Epub 2012 Jul 5.

Engineered in India--patent law 2.0.

N Engl J Med. 2013 Aug 8;369(6):497-9. doi: 10.1056/NEJMp1304400. Epub 2013 Jul 17.

Taking TRIPS to India--Novartis, patent law, and access to medicines.

N Engl J Med. 2007 Feb 8;356(6):541-3. doi: 10.1056/NEJMp068245.

The Indian Supreme Court's judgment in the case of Glivec(®) - the uncertain future of pharmaceutical patents in India.

Pharm Pat Anal. 2014 Mar;3(2):117-9. doi: 10.4155/ppa.14.8.

Supreme Court of India rejects Novartis’ cancer drug patent.

Pharm Pat Anal. 2013 May;2(3):299-300. doi: 10.4155/ppa.13.28.

Will the refusal of patent protection for Glivec® discourage future pharmaceutical innovation in India?

Pharm Pat Anal. 2013 Jul;2(4):439-41. doi: 10.4155/ppa.13.36.

Indian Supreme Court rejects Novartis's appeal on drug patent.

BMJ. 2013 Apr 2;346:f2099. doi: 10.1136/bmj.f2099.